gilead ha lot explain do thursdai nasdaq:gild seek alpha seek alpha sign inmarketplacesubscrib premium premium overview compar stock fund notabl call new dashboard top rate stock top dividend stock top reit top growth stock my portfolio all portfolio creat portfolio manag email summari manag real time email alert author my author author email alert latest stocktalk top stock rate screener etf screener latest new latest new notabl call move top new wall street breakfast ipo new m new u. economi tech new energi new healthcar new crypto new top mover earn earn new earn calendar see all section market market outlook today’ market economi gold preciou metal commod forex real estat editor pick cryptocurr global invest center stock idea long idea ipo analysi quick pick list fund letter close end fund stock idea sector stock idea editor pick short idea dividend dividend idea dividend new reit dividend strategi dividend quick pick dividend etf real estat etf dividend editor pick fix incom retir etf etf analysi etf screener editor pick let’ talk etf etf perform sector etf perform countri etf perform market cap invest strategi invest strategi editor pick portfolio strategi financi advisor podcast latest podcast wall street breakfast cannabi invest behind idea let’ talk etf sa fa marketplac roundtabl invest edg alpha trader help support knowledg base feedback forum seek alpha earn analysi healthcar gilead ha lot explain do thursdai apr 29 2020 6 10 pm et about gilead scienc inc gild shock exchang shock exchang shock street find mispric stock through fundament research both long short summari gild report earn thursdai growth could dead now hcv revenu declin yescarta' revenu stagnat recent patent infring lawsuit could further dampen yescarta' growth remdesivir ha shown progress treat covid 19 upsid difficult ignor gild remain hold sourc barron' gilead nasdaq:gild report quarterli earn april 30th analyst expect revenu 5.45 billion ep 1.57 revenu estim impli 7 declin sequenti investor should focu follow kei item revenu growth dead gilead' hiv franchis ha been stalwart compani revenu from yescarta ha been steadi hcv other product have been hit miss q4 2019 compani gener revenu 5.8 billion up 5 sequenti 2 y y i question whether gilead could maintain it previou momentum we mai find out more thursdai revenu from hiv rose high singl digit percentag rang q q biktarvi stalwart again gener 1.6 billion revenu 25 clip drug ha cannib sale some gilead' other hiv drug ha also taken share from glaxosmithklin gsk remain number on prescrib hiv regimen u. about half everi naiv switch patient initi biktarvi traction from descovi prep which launch dure quarter help drive revenu descovi up 20 q q over 25 individu prep take descovi could give drug renew life manag estim 230,000 peopl take company' hiv prevent medicin sever hundr thousand more who could potenti benefit from biktarvi descovi repres over 40 total hiv sale should remain catalyst rest year hcv revenu 630 million down high singl digit percentag rang hcv continu hamper wane price power lower patient start hcv runwai continu declin product line could still us gener cash flow gilead' total sale fall sequenti declin like driven free fall hcv sale yescarta revenu 122 million rose modestli versu q3 2019 howev regimen like catalyst investor onc thought case revenu fall two more consecut quarter gilead still ha lever pull compani report gross profit 4.2 billion down 8 q q gross margin fell sharpli 71 gilead report inventori write down 500 million due slow move raw materi work process relat hcv product sg r d cost were combin 3.1 billion san 800 million impair charg sg r d cost would have been combin 2.3 billion manag could potenti cut larg pool expens buttress bottom line gilead ha lot explain do i believ lion' share earn confer call could relat outlook yescarta remdesivir yescarta could face headwind gilead recent lost patent infring suit bristol myer nyse:bmi pursuant yescarta b cell non hodgkin lymphoma lawsuit could cost 1.2 billion judg also order kite pai run royalti 27.6 yescarta sale through expir juno' bristol therapeut unit patent 2024 gilead plan appeal verdict yet risk remain yescarta' sale tripl from 40 million q1 2018 120 million q2 2019 sinc it quarterli revenu ha been flat also ha compet novartis' nyse:nv kymriah which gener q1 2020 revenu 93 million slightli less than 96 million report q4 2019 competit from kymriah potenti royalti bristol myer could caus yescarta' revenu contribut margin fall sharpli q4 2019 net carri valu intang asset relat yescarta about 5.4 billion court rule could potenti hurt yescarta' valu trigger impair charg relat it carri valu i expect manag discuss financi impact recent court rule further detail potenti remdesivir treat covid 19 gild up over 25 year date potenti remdesivir treat covid 19 make on best perform stock drug met primari endpoint recent phase 3 clinic trial which put remdesivir track fda approv question remain what profit potenti drug compani plan donat 1.5 million dose remdesivir clinic trial compassion us program imf believ pandem ha plung world crisi stem econom carnag govern must reopen economi effect treatment covid 19 could potenti help control second outbreak make public less fear larg crowd could creat high demand fda approv remdesivir govern hospit mai need keep larg quantiti drug hand ensur access effect covid 19 could last anoth year two which mean demand effect treatment mai go awai ani time soon long wind wai sai profit potenti fda approv remdesivir could tremend conclus potenti upsid remdesivir difficult ignor gild remain hold i also run shock street invest servic part seek alpha marketplac you get access exclus idea from shock street stai abreast opportun month befor market becom awar them i am current offer two week free trial period subscrib enjoi check out servic find out first hand why other subscrib appear two step ahead market price shock street 35 per month those who sign up yearli plan enjoi price 280 per year 33 discount disclosur i we have posit ani stock mention plan initi ani posit within next 72 hour i wrote articl myself express my own opinion i am receiv compens other than from seek alpha i have busi relationship ani compani whose stock mention articl follow shock exchang get email alert add comment disagre articl submit your own report factual error articl click here your feedback matter u seek alpha rss feed advertis u sitemap about u feedback career contact u term us privaci market data disclaim 2020 seek alpha